Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mayne Pharma GroupMAYNF 54 Earnings Yield (Joel Greenblatt) % is 0.00% as of Dec. 2025. GuruFocus rates MAYNF with a GF Score™ of 54/100 and a GF Value™ of $3.57 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 121 Medical Distribution companies, Mayne Pharma Group ranks worse than 95.04% on this metric.
Mayne Pharma Group's Enterprise Value for the quarter that ended in Dec. 2025 was $150.1 Mil.
Mayne Pharma Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-26.7 Mil. Mayne Pharma Group's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 0.00%.
The historical rank and industry rank for Mayne Pharma Group's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
MAYNF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -328.62 Med: -24.37 Max: 11.09
Current: -20.12
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Mayne Pharma Group was 11.09%. The lowest was -328.62%. And the median was -24.37%.
MAYNF's Earnings Yield (Joel Greenblatt) % is ranked worse than 95.04% of 121
companies
in the Medical Distribution industry
Industry Median: 6.26
vs MAYNF: -20.12
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Mayne Pharma Group's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Mayne Pharma Group (OTCPK:MAYNF) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Mayne Pharma Group Earnings Yield (Joel Greenblatt) % Related Terms
Mayne Pharma Group Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Mayne Pharma Group's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayne Pharma Group Earnings Yield (Joel Greenblatt) % Chart
For the Medical Distribution subindustry, Mayne Pharma Group's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group Earnings Yield (Joel Greenblatt) % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's Earnings Yield (Joel Greenblatt) % falls into.
Mayne Pharma Group Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Mayne Pharma Groups Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Jun. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 0.00% mean?
Mayne Pharma Group (MAYNF) has a Earnings Yield (Joel Greenblatt) % of 0.00% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Mayne Pharma Group and its competitors. According to the industry distribution chart, Mayne Pharma Group ranks #115 out of 121 companies in the Medical Distribution industry, placing it in the top 95%.
Is Mayne Pharma Group's Earnings Yield (Joel Greenblatt) % too high?
Mayne Pharma Group's current Earnings Yield (Joel Greenblatt) % is 0.00%. Based on the distribution chart, Mayne Pharma Group ranks #115 out of 121 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Mayne Pharma Group has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Earnings Yield (Joel Greenblatt) % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #115 out of 121 companies for Earnings Yield (Joel Greenblatt) %. This places Mayne Pharma Group in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 6.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Distribution company?
The median Earnings Yield (Joel Greenblatt) % among Medical Distribution companies is 6.26, based on 121 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median Earnings Yield (Joel Greenblatt) % is 6.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current Earnings Yield (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.57, compared to a current price of $2.00 — trading 44% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 0.00%. Mayne Pharma Group's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current Earnings Yield (Joel Greenblatt) % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (MAYNF) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of $2.00 is trading 44% below its estimated GF Value™ of $3.57.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for MAYNF:
Earnings Yield (Joel Greenblatt) %: 0.00%
GF Value™: $3.57 vs. price of $2.00 (44% below fair value)
No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
54GF Score
Get the complete analysis for MAYNF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAYNF has been successfully added to your 
